Flucelvax^® is an unfunded Prescription Medicine. Flucelvax^® is an inactivated trivalent influenza vaccine, prepared in cell cultures as a suspension for injection, in a single-dose glass syringe. PRESENTATION: Each dose of Flucelvax^® Quad contains 60 micrograms/0.5 mL of surface haemagglutinin and neuraminidase from four influenza virus strains. Each dose of Flucelvax^® contains 45 micrograms/0.5 mL of surface haemagglutinin and neuraminidase from three influenza virus strains. INDICATIONS: For the prevention of influenza caused by Influenza Virus, types A and B, in adults and children 6 months of age and older. CONTRAINDICATIONS:  Known severe allergic reaction (e.g. anaphylaxis) to a previous influenza vaccination or to any component of the vaccine. ADVERSE EVENTS: Local injection site pain, erythema and induration. Systemic headache, fatigue, myalgia, irritability, nausea, upper respiratory tract infection and nasopharyngitis. Post-marketing serious adverse events includes hypersensitivity reactions, anaphylactic shock; paraesthesia, Guillain-Barré syndrome; pruritus, urticaria, or non-specific rash; Extensive swelling of injected limb. PRECAUTIONS: Postpone immunisation in patients with febrile illness or acute infection. A protective immune response may not be elicited in all vaccine recipients, particularly in immunosuppressed patients. If Guillain-Barré syndrome has occurred within 6 weeks of previous influenza vaccination, the decision to give Flucelvax^® Quad should be based on careful consideration of the potential benefits and risks. Treatment and supervision for anaphylactic reactions should be available. Co-administration with other vaccines has not been studied. DOSAGE AND ADMINISTRATION: By intramuscular injection only. Gently shake to produce a clear to slightly opalescent suspension before use. Store at 2–8°C; do not freeze; protect from light. Before prescribing, review the Flucelvax^® Data Sheet (10/2024) www.medsafe.govt.nz, Seqirus Auckland, 0800 502 757. Flucelvax^® is a registered trademark of Seqirus UK Ltd or its affiliates.

FLUAD^® is an unfunded Prescription Medicine. FLUAD^® is an inactivated influenza vaccine, with an MF59^® Adjuvant, as a suspension for injection in a single-dose glass syringe. PRESENTATION: Each dose of FLUAD^® Quad contains 60 micrograms/0.5 mL of surface haemagglutinin and neuraminidase from four influenza virus strains. Each dose of FLUAD^® contains 45 micrograms/0.5 mL of surface haemagglutinin and neuraminidase from three influenza virus strains INDICATIONS: For active immunisation against seasonal influenza for people 50 years of age and older. CONTRAINDICATIONS: Known severe allergic reactions to any component of the vaccine, except egg proteins; previous dose of any influenza vaccine. ADVERSE EVENTS: Common injection site pain, fatigue and headache. Most of these reactions disappear within 3 days. Rare but serious events include thrombocytopenia; lymphadenopathy; muscular weakness; allergic reactions such as anaphylactic shock, anaphylaxis; encephalomyelitis, Guillain Barré syndrome, neuritis, neuralgia, paraesthesia, convulsions; vasculitis with transient renal involvement; generalised skin reactions; and severe injection-site reactions (extensive limb swelling or cellulitis-like reactions). PRECAUTIONS: Postpone immunisation in patients with acute febrile illness or infection. Antibody responses may not be protective in all vaccinees, particularly in immunosuppressed patients. FLUAD^® is for intramuscular injection use only. Persons with a history of anaphylaxis to egg should be vaccinated only in medical facilities with staff experienced in recognising and treating anaphylaxis. Co-administration with other vaccines has not been studied. If Guillain-Barré syndrome has occurred within 6 weeks of previous influenza vaccination, consider potential benefits and risks. DOSAGE AND ADMINISTRATION: Gently shake before use; inject a single 0.5 mL dose into the deltoid muscle. Store at 2–8°C; do not freeze; protect from light. Before prescribing, review the FLUAD^® Data Sheet at www.medsafe.govt.nz, or from Seqirus (NZ) Ltd, Auckland. FLUAD^® is a registered trademark of Seqirus UK Ltd and its affiliates. 09/25 NZ-FLU-23-0026. TAPS DA 2508ER. Updated December 2025. INSIGHT 13414

To report an adverse event to a CSL Seqirus product click here